Heat shock proteins, such as HSP40, HSP60, HSP70 and HSP90, are known as molecular chaperones because they play a role in helping proteins function properly when cells are under stress. The heat shock response protects cells from the accumulation of misfolded proteins, aggregated proteins, and dysfunctional lysosomes (the cell’s recycling system), which could otherwise lead to toxicity and disease.
Our work is focused on making use of the cell-protective properties of HSP70 to create new therapies for rare neurodegenerative diseases.
Orphazyme A/S Company announcement No. 16/2021 Inside information Company Registration No. 32266355 Copenhagen – June 18 , 2021 – Orphazyme A/S (ORPHA.CO; ORPH), a late-stage biopharmaceutical company pioneering the heat shock protein response for the treatment of rare diseases, today
Orphazyme A/S Company announcement No. 15/2021 Company Registration No. 32266355 Copenhagen – June 11, 2021 - Orphazyme A/S (ORPHA.CO; ORPH), a late-stage biopharmaceutical company pioneering the heat shock protein response for the treatment of rare diseases, today announced that American
Orphazyme A/S Company announcement No. 14/2021 Inside information Company Registration No. 32266355 Pivotal trial did not meet primary and secondary endpoints evaluating impact on function and survival Orphazyme remains focused on commercial readiness and potential U.S.
Our Research
For Investors & Media
Working at Orphazyme